BioMarin in $289 million deal with La Jolla for lupus drug
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical has agreed to pay as much as $289 million for La Jolla Pharmaceutical's Riquent (abetimus sodium), which is in a third Phase III trial for lupus nephritis but has had a troubled past. The product has twice failed to show a statistically significant effect on renal flares associated with lupus.